-

Bayer Dedicates New Sign to Employees and Bayer Fund Donates $25,000 to Hanover Emergency Responders

Bayer Fund Awards $25,000 for COVID-19 Relief to Township of Hanover Fire District No. 3; Company Unveils New Whippany Road Sign Dedicated to Employees Working Through Pandemic

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Fund, a philanthropic arm of life sciences company Bayer, today awarded a $25,000 grant to the Township of Hanover Fire District No. 3. The donation comes as part of Bayer’s unveiling of a new sign in front of the company’s U.S. headquarters dedicated to its employees who have worked throughout the pandemic crisis.

The grant, which is earmarked for COVID-19 relief, will be used by the fire district to purchase a Fit-Tester Respiratory Protection Machine that will be used by all emergency services branches to train for and better respond to COVID-related situations.

“Just as communities across our nation have seen an increase in need this year for food donations, programming or other essential needs, the coronavirus pandemic has ushered in a host of additional challenges that require funding to tackle,” said Al Mitchell, President of Bayer Fund. “We’re proud to support the communities Bayer calls home by providing resources to help address these additional needs, allowing them to better serve citizens in need.”

The coordination of this grant with the unveiling and dedication of the new and improved Bayer sign on Whippany Road sends an important message to employees and the community, noted Raymond F. Kerins, Jr., SVP and New Jersey Site Leader for Bayer in the U.S.

“The dedication of this new sign to our employees who have worked diligently through this crisis, together with Bayer Fund’s $25,000 donation, demonstrates our commitment both to our team and to our community heroes in emergency services,” Kerins said. “What we want the Township of Hanover to know is that Bayer is right by your side, and we will continue to stand with you as all of us continue to meet and overcome the challenges associated with the pandemic.”

The $25,000 donation is the latest that the Hanover Township has received through Bayer Fund.

“On behalf of the governing body, I would like to thank Bayer and Bayer Fund once again for supporting the Hanover Township community in meaningful ways that enhance our quality of life and provide assistance to our first responders in staying safe,” said Hanover Township Mayor John L. Ferramosca.

Bayer Fund this year has designated $2 million for support related to COVID-19 relief, with the first $710,000 awarded to address food insecurity within the greater St. Louis, New York, New Jersey, Pittsburgh and Berkeley, Calif. regions.

About Bayer Fund

Bayer Fund, a philanthropic arm of Bayer, is a nonprofit organization dedicated to strengthening the communities where Bayer customers and employees live and work by providing funding for food and nutrition, education and community development projects. For more information, visit www.fund.bayer.us.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.com.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Contacts

Daniel Childs
daniel.childs@bayer.com
(973) 437-0809

Bayer Logo
Bayer Logo

Bayer


Release Summary
Bayer Fund awarded a $25,000 grant to Township of Hanover as Bayer unveiled new HQ sign dedicated to employees working through COVID pandemic crisis.
Release Versions

Contacts

Daniel Childs
daniel.childs@bayer.com
(973) 437-0809

More News From Bayer

Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome

BERLIN--(BUSINESS WIRE)--Bayer announced today initiation of a Phase IIa clinical trial with BAY 3401016, an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is thought to be involved in the progression of kidney damage in Alport Syndrome (AS), a rare genetic disorder. The first-in-patient study, ASSESS, is a randomized, double-blind, placebo-controlled, group-comparison trial (NCT07211685), with an extension phase, which will investigat...

RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, a global leader in radiology, today revealed results from the QUANTI Pediatric study, adding to the pharmacokinetic, safety and efficacy data of the investigational low-dose MRI gadolinium-based contrast agent (GBCA) gadoquatrane. QUANTI Pediatric evaluated gadoquatrane in children with known or suspected disease undergoing contrast-enhanced magnetic resonance imaging (MRI) at a gadolinium dose of 0.04 mmol Gd/kg body weight, representing a dose reduction...

Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today the start of its Phase III study SUNFLOWER, an investigational study evaluating the efficacy and safety of 52mg levonorgestrel-releasing intrauterine system Mirena® for the treatment of nonatypical endometrial hyperplasia (NAEH) in women. NAEH is an abnormal thickening of the lining of the uterus, known as the endometrium, due to an imbalance between estrogen and progesterone levels. This condition is classified as nonatypical as the cells...
Back to Newsroom